35 completed, 6 recruiting, 3 terminated, 2 active not recruiting. 47 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 47 | Completed 35, Recruiting 6, Terminated 3, Active not recruiting 2, Unknown 1 |
| Phase 2 | 6 | Completed 4, Active not recruiting 1, Terminated 1 |
Follow Biomedical Advanced Research and Development Authority: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects Fosmanogepix, Placebo, The medicine cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan and midazolam) - Healthy Adult Participants | Phase 1 | Recruiting | Basilea Pharmaceutica | 42 | 2026-10-01 | 2026-10-19 |
| A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound or Cutaneous Abscess Amicidin-β topical solution - 15 mL, Amicidin-β topical solution - 50 mL, Standard of Care (SOC) - Surgical Wound Infection, Traumatic Wound Infection | Phase 1 | Recruiting | Macro Biologics, Inc. | 44 | 2026-08-18 | 2026-11-02 |
| A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women Gepotidacin - Urinary Tract Infections | Phase 1 | Recruiting | GlaxoSmithKline | 8 | 2026-07-23 | 2026-09-30 |
| A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health rVSVΔG-SUDV-GP, Placebo - Sudan Virus Disease | Phase 1 | Recruiting | International AIDS Vaccine Initiative | 112 | 2026-05-08 | 2026-09-21 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health rVSV∆G-MARV-GP, Placebo - Marburg Virus Disease | Phase 1 | Active not recruiting | International AIDS Vaccine Initiative | 112 | 2026-03-27 | 2026-10-30 |
| A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls S-892216-PO - Renal Impairment | Phase 1 | Completed | Shionogi | 24 | 2025-10-16 | 2026-10-22 |
| A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment Cefiderocol/Xeruborbactam - Bacterial Infections | Phase 1 | Completed | Qpex Biopharma, Inc. | 40 | 2025-09-16 | 2026-09-25 |
| A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) AZD4117, AZD5315, Placebo - Influenza A | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 405 | 2025-09-04 | 2026-10-09 |
| A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults Debio 1453P, Placebo - Healthy Participants | Phase 1 | Recruiting | Debiopharm International SA | 88 | 2025-06-18 | 2026-09-22 |
| A Study of Fosmanogepix in Healthy Adult Chinese Subjects Oral Fosmanogepix, IV Fosmanogepix, IV placebo - Healthy | Phase 1 | Completed | Basilea Pharmaceutica | 54 | 2025-04-14 | 2026-04-06 |
| A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin pitavastatin, pitavastatin single dose combined with ceftobiprole - Drug-drug Interaction Study | Phase 1 | Completed | Basilea Pharmaceutica | 12 | 2025-01-17 | 2026-04-21 |
| Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil - Healthy Volunteer, Pharmacokinetics | Phase 1 | Recruiting | Basilea Pharmaceutica | 96 | 2025-01-07 | 2026-11-05 |
| Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults ARCT-2304, Control vaccine younger adults, Control vaccine older adults - Influenza, Human | Phase 1 / Phase 2 | Completed | Arcturus Therapeutics, Inc. | 212 | 2024-12-10 | 2026-09-04 |
| PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment Xeruborbactam Oral Prodrug, Ceftibuten - Bacterial Infections | Phase 1 | Completed | Qpex Biopharma, Inc. | 32 | 2024-11-10 | 2025-05-14 |
| Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults (18-55 Years) ledaborbactam etzadroxil, ceftibuten - Pharmacokinetics, Healthy Volunteers | Phase 1 | Completed | Basilea Pharmaceutica | 34 | 2024-11-04 | 2026-08-24 |
| A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants Xeruborbactam, Cefiderocol, Xeruborbactam/Cefiderocol - Bacterial Infections | Phase 1 | Completed | Qpex Biopharma, Inc. | 60 | 2024-09-04 | 2025-11-28 |
| Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA) - H7N9 Influenza | Phase 1 | Completed | Vaxxas Pty Ltd | 267 | 2024-07-31 | 2026-03-27 |
| A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults Delafloxacin, Delafloxacin Powder - Healthy | Phase 1 | Terminated | Melinta Therapeutics, Inc. | 16 | 2024-06-03 | 2026-09-11 |
| Sublingual Atropine Bioequivalence by Route of Administration (SABER) Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL) - Atropine Bioequivalence | Phase 1 | Completed | Biomedical Advanced Research and Development Authority | 46 | 2024-04-15 | 2026-01-27 |
| Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects PHV01, Placebo - Marburg Virus Disease | Phase 1 | Completed | Public Health Vaccines LLC | 36 | 2024-02-05 | 2025-09-05 |
Showing 20 of 47. Sign in to see all of them.
Bacterial Infections (10) · Infections (2) · Influenza, Human (2) · Marburg Virus Disease (2) · Virus Diseases (2) · Zika Virus Infection (2) · Anthrax (1) · COVID-19 (1) · Chronic Cough (1) · Cough (1) · Dry Eye Syndromes (1) · Hemorrhagic Fever, Ebola (1) · Hemorrhagic Fevers, Viral (1) · Keratoconjunctivitis Sicca (1) · Radiodermatitis (1)
Sodium Chloride (6) · Ceftibuten (4) · QPX7728 (4) · Atropine (2) · Cefiderocol (2) · GSK2798745 (2) · gepotidacin (2) · Adjuvants, Pharmaceutic (1) · Amoxicillin-Potassium Clavulanate Combination (1) · Boostrix (1) · Bupropion (1) · Caffeine (1) · Contraceptives, Oral (1) · Dextromethorphan (1) · Digoxin (1)
United States (36) · Australia (5) · Belgium (2) · Netherlands (2) · United Kingdom (2) · China (1) · Germany (1) · Malawi (1) · Philippines (1) · Puerto Rico (1)
Jeffery S Loutit, MBChB (3) · Jeff Loutit, MBChB (2) · Thomas Kaindl, MD (2) · Daniel Oakes, MD (1) · David Hoover, MD (1) · Derek Eisnor, MD (1) · Edward Stolarski, MD (1) · Ian Duensing, MD (1) · Janet Conway, MD (1) · Jeff S Loutit, MBChB (1) · Jeffery Loutit, MBChB (1)
PMID 36682364, PMID 34473343, PMID 38059635, PMID 39012102, PMID 39651882, PMID 41118352, PMID 41785880, PMID 41974675, PMID 42008649, PMID 42777745
2017 (2), 2019 (1)